Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steve Kallabat

Internal Medicine Bloomfield Hills, MI Medical Doctor

NPI 1245291475 CMS profile 282877

1109 W Long Lake Rd, Bloomfield Hills, MI 48302

Open in the dashboard

General payments

$8,896

427 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steve Kallabat of Bloomfield Hills, MI is reported in the CMS Open Payments database as having received $8,896 across 427 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,655 85
2024 General $1,956 87
2023 General $2,074 92
2022 General $1,318 74
2021 General $921 42
2020 General $315 19
2019 General $658 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steve Kallabat
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steve Kallabat were reported at $1,655. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steve Kallabat Internal Medicine median Middle half National median
2019 $658 $159 $48–$570 $163
2020 $315 $119 $33–$402 $114
2021 $921 $135 $37–$521 $132
2022 $1,318 $141 $42–$496 $149
2023 $2,074 $149 $45–$519 $160
2024 $1,956 $154 $47–$537 $164
2025 $1,655 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,669 77 payments
  2. AbbVie, Inc. $1,074 43 payments
  3. Novo Nordisk Inc $956 68 payments
  4. GlaxoSmithKline, LLC. $791 20 payments
  5. AstraZeneca Pharmaceuticals LP $490 28 payments
  6. Biohaven Pharmaceuticals, Inc. $389 9 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $386 21 payments
  8. Lilly USA, LLC $344 16 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $264 16 payments
  10. Exact Sciences Corporation $217 12 payments
  11. Other $2,316 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,689 426 payments
  2. Debt forgiveness $208 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT Primary Care $653 25 payments
  2. EUCRISA $632 30 payments
  3. NURTEC ODT Pain $566 30 payments
  4. UBRELVY $560 24 payments
  5. ZAVZPRET $491 21 payments
  6. QULIPTA $451 13 payments
  7. Ozempic $431 32 payments
  8. RYBELSUS $431 32 payments
  9. COLOGUARD $426 26 payments
  10. Wegovy $415 23 payments
  11. Other $6,720 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

4,637

Median for Internal Medicine: 777

Drug cost

$514,686

Median for Internal Medicine: $73,373

Branded share of claims

25%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 104 $81,769
Jardiance Empagliflozin Brand 69 $67,568
Eliquis Apixaban Brand 72 $61,775
Mounjaro Tirzepatide Brand 52 $52,831
Januvia Sitagliptin Phosphate Brand 55 $41,322
Ozempic Semaglutide Brand 43 $40,307
Repatha Sureclick Evolocumab Brand 26 $18,359
Xarelto Rivaroxaban Brand 11 $18,130
Qulipta Atogepant Brand 13 $12,866
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $12,762

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$149,811

Of which drugs: $16,246

Medicare patients

313

Average age 74

Services billed

2,456

167 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 30%
Ischemic heart disease 29%
Diabetes 23%
Atrial fibrillation 16%
Cancer 15%
Depression 15%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 28 28 $8,105
Vaccine for influenza for injection into muscle 90662 Office 95 95 $7,652
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 59 $44

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $187
$187 13 —
AREXVY
  • GlaxoSmithKline, LLC. $167
$167 — —
VRAYLAR
  • AbbVie, Inc. $155
$155 — —
MOUNJARO
  • Lilly USA, LLC $146
$146 52 —
BEXSERO
  • GlaxoSmithKline, LLC. $128
$128 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

427 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record